Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ramucirumab and Atezolizumab in NSCLC
NCT03689855Phase 2Completed
- Sponsor
- Washington University School of Medicine
- Start
- Jun 2019
- Primary completion
- Jul 2021
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ramucirumab in non-small cell lung cancer (NSCLC), sponsored by Washington University School of Medicine. Started Jun 2019; status: completed.
02
Drugs
ramucirumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03689855.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03689855.